View Post

Intensity Therapeutics Receives Fast Track Designation from U.S. FDA for Development of INT230-6 as Treatment for Relapsed or Metastatic Triple Negative Breast Cancer

In Clinical Trials by Barbara Jacoby

Source: Intensity Therapeutics Inc From: globenewswire.com Intensity Therapeutics, Inc., a clinical-stage biotechnology company pioneering a novel, immune-based approach to treat solid tumor cancers through direct injection of its proprietary therapeutic agents, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company’s development program evaluating INT230-6 for the treatment of patients with relapsed …

View Post

California Protons Cancer Therapy Center Invites Patients to Enroll in Breast Cancer Study and Clinical Trial

In Clinical Trials by Barbara Jacoby

Source: Business Wire From: apnews.com California Protons Cancer Therapy Center today announced two major efforts representing significant steps forward in breast cancer treatment research involving its noninvasive, targeted proton therapy. Current California Protons patients as of Feb. 4, 2019, are invited to enroll in the Proton Collaborative Group (PCG) Registry of more than 13,000 patients. Separately, the PCG BRE007-12 Partial …

View Post

Triple negative breast cancers can adopt reversible state that is resistant to chemotherapy

In In The News by Barbara Jacoby

Source: University of Texas M. D. Anderson Cancer Center From: eurekalert.org Study finds that resistant cells become vulnerable to MD Anderson-developed targeted therapy Researchers at The University of Texas MD Anderson Cancer Center have discovered that triple negative breast cancer (TNBC) cells can develop resistance to frontline, or neoadjuvant, chemotherapy not by acquiring permanent adaptations, but rather transiently turning on …

View Post

Adjuvant AI Breast Cancer Therapy May Cause Long-Term Cognitive Decline

In In The News by Barbara Jacoby

By: BETH FAND INCOLLINGO From: oncnursingnews.com The cognitive function of postmenopausal women who take hormonal maintenance therapy after surgery for breast cancer remains compromised after the regimen’s 5-year course, according to study results presented at the ONS 44th Annual Congress in Anaheim, California, April 12. Catherine M. Bender, Ph.D., RN, FAAN, and colleagues embarked on the study because they and …

View Post

New breast cancer gene puts younger women at risk

In In The News by Barbara Jacoby

By: Sharp Grossmont Hospital Health News Team From: eccalifornian.com Michelle Buckley was a busy single mom raising two teenagers. As a physical therapist assistant at Sharp Grossmont Hospital, she understood the importance of keeping fit. She exercised, ate healthy food and got regular checkups. She was also a firm believer in breast self-exams because 10 years prior, at age 32, …

View Post

GlycoMimetics Announces Plans to Initiate Breast Cancer Trial to Evaluate GMI-1359

In Clinical Trials by Barbara Jacoby

Source: Business Wire From: apnews.com GlycoMimetics, Inc. (NASDAQ: GLYC) today announced plans to initiate a clinical trial of GMI-1359 in breast cancer patients whose tumors have spread to bone. GMI-1359 is a dual function antagonist that targets both E-selectin and CXCR4, both of which are involved in tumor trafficking and metastatic spread. The trial will evaluate dose escalation as well …

View Post

Cognitive-Behavioral Therapy Reduces Endocrine Treatment Side Effects in Breast Cancer Patients

In Clinical Trials by Barbara Jacoby

By: Lidia Schapira, MD From: medscape.com Efficacy of Internet-Based Cognitive Behavioral Therapy for Treatment-Induced Menopausal Symptoms in Breast Cancer Survivors: Results of a Randomized Controlled Trial Study Summary Adjuvant endocrine therapy for breast cancer, through treatment-induced profound estrogen deprivation, leads to hot flashes (HF) and night sweats (NS). These symptoms affect women’s daily functioning and health-related quality of life and, …

View Post

Gold nanoparticle delivery of microRNA impairs metastasis in triple-negative breast cancer

In In The News by Barbara Jacoby

By: Weill Cornell Medical College From: medicalxpress.com Weill Cornell Medicine researchers have shown that giving mice with triple-negative breast cancer therapeutic microRNA (miRNA) in a protective gold nanoparticle results in significantly less spreading of cancer to the lung. Triple-negative breast cancer is a highly aggressive, difficult-to-treat form of the disease, with a high rate of metastatic recurrence. miR-708 is a …

View Post

Valuable Information for Cancer Patients and Their Loved Ones in A Live Online Event

In Uncategorized by Barbara Jacoby

Calling All Cancer Patients, Cargivers and Loved Ones! Don’t miss out on this Facebook Live interview on Thursday May 9, 2019 at 2 pm ET. Johns Hopkins School of Medicine Professor of Breast Cancer Lillie D. Shockney, RN will share information regarding reporting the side effects of cancer treatments and how to support a loved one that should be extremely …